392690-97-0

Upstream product

• 138163-08-3 N-(benzyloxycarbonyl)piperidine-4-carboxaldehyde 
• 508234-07-9 ethyl 4-[4-(hydroxymethyl)-1-piperidyl]benzoate 
• 508234-08-0 4-(4-formyl-piperidin-1-yl)-benzoic acid ethyl ester 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 6457-49-4 4-piperidinemethanol 

Relevant academic research and scientific papers

Chimeric compound for targeted degradation of androgen receptor protein, preparation method of chimeric compound and application of chimeric compound in medicine

The invention relates to a chimera compound for targeted degradation of androgen receptor protein, a preparation method of the chimera compound and application of the chimera compound in medicine. Specifically, the invention relates to a chimera (PROTAC) compound for targeted degradation of AR protein of a fused heterocyclic cerebellar protein (cerebellone) E3 ubiquitin ligase ligand as shown in a general formula (IM), a preparation method of the chimera compound, and application of the chimera compound in medicine, and particularly relates to a chimera (PROTAC) compound for targeted degradation of AR protein of a fused heterocyclic cerebellar protein E3 ubiquitin ligase ligand of a fused heterocyclic cerebellar protein E3 ubiquitin ligase ligand.

Novel substituted 4-aminomethylpiperidines as potent and selective human β3-agonists. Part 2: Arylethanolaminomethylpiperidines

The synthesis and SAR of a series of β3 adrenoreceptor agonists based on a novel template derived from 4-aminomethylpiperidine coupled with a common pharmacophore, arylethylamine, is described. This combination led to the identification of human β3 adrenoreceptor agonists with in vivo activity in a transgenic mouse model.